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CLINICAL SNIPPETS
Defense Mechanism
Dermcidin (DCD) is an antimicrobial peptide 
with broad-spectrum activity, produced by 
eccrine glands and secreted into sweat. Rieg 
and co-workers investigated the proteolytic 
processing, site-specific expression, and stabi-
lity of DCD peptides in eccrine sweat. At body 
sites with a high probability of contact with 
pathogenic microorganisms, multiple active 
DCD peptides were detected in sweat. During 
prolonged sweating, the secretion rate of DCD 
was constant, and DCD peptides were stable in 
sweat over several hours. DCD-derived antimi-
crobial peptides contribute to the first line of 
defense. See page 354 
Building Better Barriers
Peroxisome proliferator-activated recep-
tors (PPARs) and liver X receptor (LXR) 
activators stimulate epidermal lipid syn-
thesis, increase lamellar body secretion, 
and accelerate extracellular lipid pro-
cessing. Man and co-workers studied the 
effects of topical PPARs and LXR activa-
tors on the lipid matrix of the stratum 
corneum of hairless mice. These newly 
identified effects are additional mecha-
nisms (besides epidermal differentiation) 
for improving epidermal permeability 
barrier homeostasis. One conclusion: since liposensors are activated by endoge-
nous lipid metabolites, they may serve as unique regulators of barrier homeostasis. 
Drugs affecting PPARs and LXRs abound, and their effects on epidermal structure 
and function deserve close scrutiny. See page 386 
Your Mom Counts
During pregnancy, cells from mother and 
fetus can transfer both ways, and some 
maternal cells have been found in patients 
as old as 49 years. Khosrotehrani and col-
leagues identified and phenotyped mater-
nal cells in lesional skin of male children 
with inflammatory skin disorders, espe-
cially pityriasis lichenoides (PL). Maternally 
derived keratinocytes were found in both 
PL patients (11 of 12) and controls (4 of 7), 
but the average frequency was higher in 
PL patients: 99 per million cells compared 
with 5 per million cells in controls. These cells may either help repair the disease, 
or home initially in the skin and trigger a host (child)-versus-graft (mother) disease. 
See page 345 
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Nystatin: New 
Actions
Dendritic cell (DC) matura-
tion is the key event incit-
ing many powerful immune 
responses. Ogawa and 
co-workers developed a 
biosensor system to detect 
DC-stimulatory signals. Their 
findings now document novel 
pharmacologic activities of 
nystatin to induce phenotypic 
maturation and cytokine/
chemokine production by 
DCs. Further in vivo stud-
ies in experimental animals 
and human patients will be 
needed to assess the clinical 
significance of these in vitro 
findings, but the study pro-
vides new insights into mech-
anisms of action of nystatin, a 
medication used commonly 
for the treatment of super-
ficial Candida albican fungal 
infections. See page 349 
Pompholyx Gene
Pompholyx is a common 
disorder characterized by 
recurrent crops of intensely 
pruritic, burning, vesicobul-
lous eczema on the palms and 
soles. Chen and colleagues 
mapped the chromosome 
location of the responsible 
gene as 18q22.1–18q22.3. The 
precise identification of that 
gene may be useful in fully 
understanding the molecular 
mechanism of pompholyx and 
may be integral in the devel-
opment of effective treatment 
options. See page 300 
